Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Regular paracetamol use could reduce ovarian cancer risk by almost a third

06.07.2006
Using paracetamol regularly could reduce the risk of ovarian cancer by almost a third, according to a detailed analysis in the July issue of British Journal of Clinical Pharmacology.

A research team from Athens University found that the risk fell by up to 30 per cent when they analysed the results of major studies carried out on more than 746,000 women over a six-year period.

4,405 of the women in the eight major studies – from the USA, UK and Denmark – had ovarian cancer.

The team looked at all studies covering paracetamol and ovarian cancer from 1966 to 2004. These were then scrutinised using sophisticated meta-analysis techniques.

“Meta-analysis involves doing a large amount of research into what has been published, summarising the results and combining them using statistical methods” explains lead researcher Dr Stefanos Bonovas from the Greek Ministry of Health. “Analysing a wide range studies can often throw new light on a problem and raise new research questions.

“In this case our analysis of eight major studies – covering nearly three-quarters of a million women - revealed a strong correlation between paracetamol use and a reduced risk of ovarian cancer.”

Seven of the studies looked at the links between paracetamol use and the incidence of ovarian cancer and the largest study looked at the link between paracetamol use and ovarian cancer deaths.

The researchers used a working definition of “regular use” as the highest frequency of drug use reported in the individual studies. This definition varied slightly between studies. In the largest study – which covered more than a third of the women diagnosed with ovarian cancer – it was defined as more than 30 tablets in the month before the study started.

“Ovarian cancer remains the most fatal gynaecological malignancy” says Dr Bonovas. “Its high mortality rate – mainly due to a combination of ineffective screening and the limited success of therapies for advanced disease - makes ovarian cancer a major health concern.

“Strategies that focus on prevention may therefore provide the most rational approach for reducing deaths from this form of cancer.

“Because paracetamol is so widely used, a link with a decreased risk of ovarian cancer could have important public health implications.”

The authors believe that further research among women with a high risk of developing ovarian cancer would provide further clues to the drug’s protective qualities.

“The risks of long-term paracetamol use - including liver and chronic kidney failure – may outweigh the potential benefits of preventing ovarian cancer in low-risk cases” concludes Dr Bonovas.

”However we believe that a randomised trial in women with a high risk of developing the disease might be appropriate. Further research is also needed into how this protective mechanism actually works.

The authors stress that they are not suggesting that women adopt this possible method of risk prevention at this stage.

“But we do feel that our study highlights the need for further research into this highly important link between a simple over-the-counter medicine and a very aggressive form of cancer” says Dr Bonovas.

Dr Bonovas works for the Department of Epidemiological Surveillance and Intervention at the Greek Ministry of Health’s Hellenic Centre for Infectious Diseases Control and carries out his research at Athens University.

This study was carried out in association with University researcher Dr Kalitsa Filioussi, under the supervision of Dr Nikolaos M Sitaras, Associate Professor of Medicine in the Department of Pharmacology.

Annette Whibley | alfa
Further information:
http://www.blackwellpublishing.com/bjcp

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>